718-1355

completed

Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
718 (USA) · Dr. Nolan

consented 2013-02-28

AEs
13
Serious
0
Dropout signal

Adverse events

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2013-04-27 (study day 59.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2013-05-12 (study day 74.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2013-05-16 (study day 78.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE DERMATITIS — outcome: RECOVERED/RESOLVED; onset 2013-05-20 (study day 82.0); relationship: PROBABLE

mild assessed

Mild APPLICATION SITE REACTION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-06-23 (study day 116.0); relationship: PROBABLE

moderate assessed

Moderate APPLICATION SITE REACTION — outcome: RECOVERED/RESOLVED; onset 2013-06-23 (study day 116.0); relationship: PROBABLE

moderate assessed

Moderate CONFUSIONAL STATE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-04-17 (study day 49.0); relationship: REMOTE

moderate assessed

Moderate DERMATITIS ATOPIC — outcome: NOT RECOVERED/NOT RESOLVED; onset 1982; relationship: NONE

moderate assessed

Moderate HYPERTENSION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-15 (study day 169.0); relationship: REMOTE

moderate assessed

Moderate HYPERTENSION — outcome: RECOVERED/RESOLVED; onset 2013-08-15 (study day 169.0); relationship: REMOTE

moderate assessed

Moderate SKIN ULCER — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-03-08 (study day 9.0); relationship: PROBABLE

moderate assessed

Moderate SKIN ULCER — outcome: RECOVERED/RESOLVED; onset 2013-03-08 (study day 9.0); relationship: PROBABLE

moderate assessed

Moderate SOMNOLENCE — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-25 (study day 87.0); relationship: NONE

Data queries

No data queries.